| abstract |
The present invention relates to a compound of the formula (I),n□ where A has the meaning of CH or a nitrogen atom; R means hydrogen or a halogen atom or a C1-C6 straight or branched alkyl group; R1 means hydrogen or a halogen atom, or a C1-C6 straight or branched alkane a C1-C6 straight or branched alkoxy group, or a mono- or polyhalogenated C1-C6 straight or branched haloalkyl group; R2 means hydrogen or a halogen atom, or a C1-C6 straight chain Or a branched alkyl group, or a C1-C6 straight or branched alkoxy group, ornMono- or polyhalogenated C1-C4 straight or branched haloalkyl; R3 means hydrogen, or C1-C6 straight or branched alkyl optionally substituted by C3-C6 cycloalkyl, or a mono- or polyhalogenated C1-C6 linear or branched haloalkyl group; or a C3-C6 cycloalkyl group, or a C1-C6 straight or branched alkane group, and/or a salt thereof, and/or its geometry Isomers, and/or stereoisomers thereof, and/or their non-image isomers, and/or hydrates thereof, and/or solvates thereof, and/or polymorphic modifications thereof.nThe present invention relates to novel substituted diazaindenoindole derivatives of the general formula (I), and pharmaceutically acceptable salts thereof, and pharmaceutical compositions comprising the same, new intermediates thereof, and the like The use of a compound for treating or preventing a condition associated with melanin-concentrating hormone receptor 1 activity. |